Synergistic Trigeminal Pain Molecules in a Model of Traumatic Brain Injury:
Implications for Post-Traumatic Headache
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Introduc.on	
  
Headache following traumatic brain injury (TBI) is highly prevalent, and
also the most common and persistent symptom of post-concussion syndrome
[1,2]. It could also arise de novo or as a pre-existing headache disorder, in
which migraine was the most frequent headache phenotype in both civilian
and military patients with mild TBI [1,2]. Most post-traumatic headaches will
resolve within a couple of weeks following injury; however, headache in a
substantial subset of patients it may last more than three months and
contribute to a prolonged recovery from injury, disability, and a poor quality of
living [2]. Headaches can persist well beyond the acute inflammatory period,
necessitating intervention and preventative strategies for chronic posttraumatic headache as a time-sensitive problem to address.
Key pain signaling molecules, calcitonin gene-related peptide (CGRP) and
nitric oxide synthase (NOS), play a role in post-traumatic headache
pathophysiology as they do for migraine. CGRP and NO/NOS are proposed to
have reciprocal feedback mechanisms in the trigeminovascular system.
CGRP, a well-studied nociceptive neuropeptide in pain and migraine fields,
increases in the trigeminal pain system after TBI [3]. A recent study by our
laboratory noted significant iNOS positive cells from a microglial and/or
macrophage source in the cortical area proximal to the injury [4]. Typically,
iNOS is characterized locally at the injury site making the trigeminal pain
circuit, an area remote from the injury site, a novel site to investigate. Nitric
oxide triggers headache in migraineurs and animal models via abnormal
activation of the trigeminovascular system. Nitric oxide is produced by
different isoforms of the nitric oxide synthase (NOS) enzymes. Of the NOS
isoforms, the inducible isoform was investigated as inflammation is a
predominant feature of TBI and post-traumatic headache. Therefore, the
goals of this research were threefold: (1) to investigate if iNOS gene and
protein expression in the trigeminal ganglia and trigeminal nucleus caudalis
(TNC) are altered in a murine model of controlled cortical impact (CCI) injury,
(2) to identify the cellular source for changes in the expression of iNOS, and
(3) to examine the proposed synergism between CGRP and iNOS in an in
vivo model of TBI.

Methods	
  
Model of Traumatic Brain Injury
Traumatic brain injury (TBI) was induced in mice using a CCI injury model as
described previously by our laboratory [3,4,5]. Animals were anesthetized with
isoflurane (3% induction; 2-2.5% maintenance). A right-sided 4 mm
craniotomy was performed. CCI was induced using an electromagnetic
stereotaxic impactor (Leica Biosystems) at 1.0 mm depth, 3.0 m/sec (100 ms
contact time) at a 90° impact angle to the cortical surface.
Experimental Design and Outcomes:
Pharmacotherapies known to alter the actions of CGRP, a CGRP antagonist
(MK8825; 100 mg/kg) and sumatriptan (1 mg/kg), were administered i.p. for
two consecutive days during week two post-injury (on day 13 and 14) and
compared to saline controls. All treatment group’s endpoints were at two
weeks after injury. The effects of treatment on iNOS mRNA and protein were
determined in the trigeminal ganglia and TNC using quantitative RT-PCR and
immunohistochemistry. The cellular source and distribution of iNOS was
assessed. In separate experiments, the effects of CCI in iNOS knockouts
(KO) were compared to wild-type mice with CCI on CGRP levels in the TNC
using an ELISA. There were two endpoints examined for iNOS KO groups: 3
days and 2 weeks.
Sensory behavior indicative of headache, trigeminal allodynia and
photophobia were also measured in all groups. Trigeminal allodynia testing
was performed as previously described using von Frey thresholds (Macolino
et al., 2014). Photophobia, an aversion to light, has been shown in mouse
models overexpressing CGRP to study migraine [6]. Mice are placed in the
white plexiglass illuminated compartment with either ambient ceiling lighting
(approx. 200 lux), or under bright light (approx. 600 lux; Utilitech). For treated
groups, testing was performed under bright light conditions. The time spent in
the light compared to the darkened black compartment is recorded along with
exploratory behaviors using the ANYmaze software (Stoelting).
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Results	
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Figure	
  1:	
  Trigeminal allodynia measured by von Frey filaments on
the sides ipsilateral and contralateral to controlled cortical impact
(CCI) injury. Wild-type CCI mice treated with sumatriptan and
MK8825 compared to vehicle, *p<0.05, **p<0.01. iNOS knockout
(KO) compare to vehicle-treated CCI wild-type mice were not
statistically significant.
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aversion to bright light (~600 lux)
compared to ambient light (~200 lux)
conditions. (A) Percentage of time spent
in the bright light compartment during was
reduced during bright light exposure for
wild-type CCI mice treated with vehicle
compared to naïve mice, **p<0.01. There
were no group differences under ambient
light conditions. (B) % time spent in the
bright light compartment for CCI groups
treated with SUMA, MK8825 and iNOS
KO compared to VEH *p<0.05 and **
p<0.01, and naïve ### p<0.001. (C)
Transitions compared to VEH, **p<0.01.
(D) Number of rears in the light
compartment compared to VEH, *p<0.05,
**p<0.01, **p<0.001, and to naïve mice,
p<0.05.
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Figure 4. Trigeminal ganglia cells labeled for ionized calcium binding
adapter 1 (IBA-1) positive microglia, glial fibrillary acidic protein
(GFAP) positive satellite, and iNOS markers. GFAP satellite cells (A)
IBA-1 microglia cells (B) sit juxtaposed between neurons in the
trigeminal ganglia and have distinct cellular morphologies. After
injury, iNOS is expressed by cells with a neuronal morphology
indicated by arrows and by non-neuronal cells indicated by arrow
heads (C and D), scale bars = 10 µm.	
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Figure 3. Immunofluorescent iNOS labeled trigeminal ganglia
cells (A) The number of iNOS positive cells at two weeks postoperatively in incision control, CCI treated with vehicle (VEH),
sumatriptan (SUMA), and MK8825, ####p<0.0001 compared to
control, and ****p<0.0001 compared to vehicle. (B-F) Images
showing iNOS immunofluorescently labeled ganglia cells. (B)
low power image showing a trigeminal ganglia section with the
opthalamic V1 region of interest (box) indicated, scale bar = 200
µm. High power images of the ganglia from (C) control, and CCI
groups treated with (D) vehicle,
(E) sumatriptan and (F)
MK8825, scale bar = 10 µm.

Figure 5: Images showing iNOS
(red), CGRP (green) and colocalization (yellow) in the (A-C)
trigeminal ganglia and trigeminal
nucleus caudalis (D-F). iNOS and
CGRP (yellow) co-localize in the
TNC (F).
In trigeminal ganglia
cells, co-localizarion is shown;
some
CGRP
positive
cells
(arrowheads) do not co-localize
with iNOS (arrows) . Bar = 100 µm.

Figure	
  7:	
  Images	
  showing	
  iNOS	
  immunoreac;vity	
  in	
  the	
  TNC. A) Inducible NOS appears as possible
cytosolic small vesicles, granules, submembranal cytoskeletal attachments, and perinuclear aggresomes,
although the full characterization of these distinct molecular entities and their significance remain elusive.
iNOS (red) double labeling with B) IBA-1+ microglia (green) and C) GFAP+ astrocytes do not show a clear
cellular co-localization.
	
  

Figure 6 LEFT: iNOS mRNA levels in the TNC were increased
after CCI compared to control, ##p<0.01, whereas treatment with
SUMA and MK8825 reduced iNOS mRNA compared to vehicle,
**p<0.01, ***p<0.001. BOTTOM LEFT: Atlas of mouse medulla
showing the TNC/SPVC region outlined in light grey and the
ophthalamic V1 RO1 (BOX); source: Allen Institute for Brain
Science. RIGHT: Images showing iNOS immunoreactivity in the
TNC V1 region (A) in the uninjured control is negligible, (B)
increased in the CCI mice treated with vehicle, (C) reduced in
sumatriptan treated mice, and (D) reduced in MK8825 treated
mice. Scale bar = 100 µm,
Figure 8: CGRP levels
in the TNC at 3 days
after CCI in wild-typevehicle (n=6) and iNOS
KO (n=4) mice, and at
2 weeks in wild-typevehicle (n=8), iNOS KO
mice (n=5) and
sumatriptan mice (n=8)
*** p<0.001, **p<0.01.

Conclusions	
  
§ Synergism between iNOS and CGRP in the trigeminal pain pathway was demonstrated
in an in vivo model of TBI. Findings indicate the significance of this relationship
contributes to the exacerbation of trigeminal allodynia following injury.
§ Although photophobia may be mediated via CGRP and iNOS mechanisms, these
pathways may participate independently in the activation of photo-sensitive neurons.
§ At the level of the trigeminal ganglia, iNOS is expressed by neuronal and non-neuronal
cell type.
§ Blockade of CGRP has therapeutic potential in the management of post-traumatic
headache, especially in which there may be a delayed therapeutic window.
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